Virtual Library

Start Your Search

Patricio Santillan Doherty



Author of

  • +

    P2.06 - Mesothelioma (Not CME Accredited Session) (ID 955)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P2.06-30 - Association of Histopathological Patterns of Mesothelioma and Response to Treatment with Chemotherapy (ID 13799)

      16:45 - 18:00  |  Author(s): Patricio Santillan Doherty

      • Abstract
      • Slides

      Background

      Mesothelioma is a neoplasm with a high mortality, there are different prognostic factors that influence survival, within these, the histological type has been associated directly.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      Descriptive, observational, retrospective and unicentric study, that analyzes the response of the different histopathological patterns of malignant pleural mesothelioma to chemotherapy. The study had 28 patients pathologically diagnosed with malignant pleural mesothelioma between April 2014 to August 2015 at the National Institute of Respiratory Diseases. The primary objectives were overall survival and mesothelioma histopathological patterns variable, and secondary objectives was progression free survival and response rate to chemotherapy based on RECIST 1.1.

      4c3880bb027f159e801041b1021e88e8 Result

      The sample was formed by 18 men (64%) and 10 women (36%), 57% had asbestos exposure and 43% another exhibition (textile, fiber glass, cement, fertilizer, petroleum, solvents and coal). The 46% were smokers with an average of 6.6 packs/year. The method of biopsy as a diagnostic was thoracoscopy, which was used in 57% of the patients. The 94.4% had epithelioid pattern and 3.6% biphasic; in the epithelioid pattern, the solid subtype was the most predominant with 51.8%, followed by tubulopapillary with 14.9%, acinar with 14.8%, papillary and micropapillary both with 7.4% and pleomorphic with 3.7%. In overall survival and progression-free survival were higher the subtypes: micropapillary with 27 months, solid with 23 and 20 months, tubulopapillary with 20 and 18 months and acinar with 15 and 17 months respectively, the poorer prognosis was pleomorphic subtype with 4 months, similar to the biphasic pattern with 6 months. The median progression free survival for all patients was 17 months, the men were higher to the women with 17 and 12 months respectively. We found a relationship between overall survival and the nuclear calretinin, with a better prognosis for that patients who are not expressers (27.3 months) comparative to that patients with any level of expression (17 months). Within the therapeutic schemes used in the first line, by permetrexed plus cisplatin was superior to others in the disease-free survival; in the compound of platinum, the combined with cisplatin proved to be superior, not influencing the therapeutic scheme in the overall survival.

      8eea62084ca7e541d918e823422bd82e Conclusion

      The histopathological pattern is a prognostic factor in progression free survival and overall survival. Nuclear calretinin is a prognosis factor. The best therapeutic scheme of front line was permetrexed plus cisplatin in progression free survival, cisplatin schemes offer a better PFS compare to carboplatin schemes, not influencing in the overall survival.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.